Home>Video>Prescribe to Pharma for Emerging-Markets Growth

Prescribe to Pharma for Emerging-Markets Growth

Thu, 12 Dec 2013

Many developed-country health-care firms have deep roots in emerging markets and can be a good way to gain exposure, says Morningstar's Damien Conover.


Video Transcript

Emma Wall: I'm Emma Wall. And here with me today is Morningstar analyst, Damien Conover. Hello, Damien.

Damien Conover: Hi, Emma. Thanks for having me.

Wall: Today, we are going to talk about emerging-markets revenues, but through developed-markets-listed stocks because emerging markets have not done very well over the last couple of years, have they, whereas the U.S. stock market, is up 30% so far this year?

Conover: I think that's a great way to get exposure to emerging markets, to go through some of these firms that have much more exposure to the developed markets, but yet also have a large exposure to the emerging markets which is growing rapidly. I think it's important to have exposure to some of those geographies.

Wall: And what's your first stock today?

Conover: The first one I talk about is Sanofi. Sanofi has one of the leading exposures of the big pharmaceutical firms to emerging markets. It's very well entrenched in vaccines and diabetes [treatments]. Those are two therapeutic areas that emerging markets really want to have exposure to. So we think the stock is undervalued, and a big piece of the reason why we think it's undervalued is the exposure to the emerging markets.

Wall: And what emerging markets is it exposed to?

Conover: It's really across the board. It's Brazil, it's Russia, it's India, but most importantly it's China. China is, in our view, the most important emerging market, and Sanofi has very strong entrenchment there which should bode well for the stock.

Wall: And what's your second stock?

Conover: The next stock to talk about is Teva. Teva is a stock that has a lot of risk overhang with a patent loss on Copaxone, one of its key products. But one of the strategies Teva is employing to get beyond the Copaxone patent loss is its exposure to emerging markets in the branded generics market, which we believe Teva is one of the best firms positioned to take advantage of the growing demand for branded generics in the emerging markets.

Wall: So this patent cliff, that is not something to be concerned about?

Conover: It is to be concerned about. But we think it's factored into the stock's valuations. The stock is trading very, very low on a P/E basis, and we think investors are overly focused on the patent loss, but not thinking about some of the strategies we think will do quite well for Teva over a longer term, including the exposure to the emerging markets.

Wall: And what about in the U.K., is there a stock that displays these characteristics?

Conover: Yes. The stock that we like, that's more U.K.-based and also has good exposure to the emerging markets is GlaxoSmithKline. They've run into some challenges in China; we think they'll get through that. But it's not just China that they have exposure to but a lot of the other really important emerging markets. GlaxoSmithKline is well entrenched in the respiratory disease franchise, and we expect that to bode very, very well for them in the emerging markets.

Wall: Also pays quite a nice dividend, isn't it?

Conover: Yes, a great dividend, a secure dividend, and a nice way to get some return in a market environment where it's hard to get those yields.

Wall: Thank you very much, Damien

Conover: Thanks for having me, Emma.

Wall: This is Emma Wall for Morningstar. Thank you for watching.

  1. Related Videos
  2. Related Articles
  1. Emerging Markets Not Really a Bargain

    Lower valuations reflect a slower growth environment, with currency volatility continuing to affect certain markets in the near term, says Morningstar's Patty Oey.

  2. Emerging Markets : Great Potential for the Patient

    The growth story is intact for emerging markets , but it won't unfold overnight, says Seafarer Capital Partners CIO Andrew Foster.

  3. Hasenstab's Guidelines for Emerging Markets

    Templeton Global Bond manager Michael Hasenstab outlines his criteria for investing in developing markets, and explains why he sees opportunities in China and Korea.

  4. Go Active or Passive in Emerging Markets ?

    For investors who are worried about overexposure to China's volatile market, active funds may be a better option, says Morningstar's Patty Oey.

  5. Health Care the Next Chapter of China's Growth Story

    Consumption-led industries will drive Chinese growth for the next decade, and health-care spending, in particular, should outpace China's overall economy, says Morningstar's Dan Rohr.

  6. Smarter International Investing

    Morningstar's Patty Oey and Dan Rohr and Columbia Acorn's Andreas Waldburg-Wolfegg offer best practices for globe-trotting investors who must navigate choppy waters in today's market.

  7. Will U.S. Hit a BRIC Wall?

    Slowing in some emerging markets likely affects other emerging markets more than it harms the U.S. economy, says Morningstar's Bob Johnson.

  8. Emerging Markets : What to Know Before You Go

    We dig into recent performance, the role of reforms, and concentration issues with some emerging - markets indexes.

©2017 Morningstar Advisor. All right reserved.